Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 15, 2023 at 06:49 am EST
Share
Skinvisible, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.005 million compared to USD 0.009316 million a year ago. Net loss was USD 0.287518 million compared to USD 0.418068 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 0.09 a year ago.
For the nine months, sales was USD 0.015 million compared to USD 0.274296 million a year ago. Net loss was USD 2.08 million compared to USD 0.82431 million a year ago. Basic loss per share from continuing operations was USD 0.46 compared to USD 0.18 a year ago. Diluted loss per share from continuing operations was USD 0.46 compared to USD 0.18 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.